{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"63.0"},{"groupId":"OG001","value":"22.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"200"},{"groupId":"OG001","value":"97"}],"units":"Participants"}],"description":"Defined as the percentage of participants with a complete response (CR), partial response (PR), and stable disease (SD) according to modified RECIST Version 1.1 with no progression in bone per PCWG3 criteria.","groups":[{"description":"Oral rucaparib (monotherapy).\n\nRucaparib: Rucaparib will be administered daily.","id":"OG000","title":"Rucaparib"},{"description":"Oral abiraterone acetate (monotherapy, given in combination with prednisone). Oral enzalutamide (monotherapy). Intravenous docetaxel (monotherapy, given in combination with prednisone or prednisolone).\n\nAbiraterone acetate or Enzalutamide or Docetaxel: Abiraterone acetate and enzalutamide will be administered daily.\n\nDocetaxel will be administered every 3 weeks.","id":"OG001","title":"Abiraterone Acetate or Enzalutamide or Docetaxel"}],"paramType":"NUMBER","populationDescription":"The Safety Population included all participants with BRCA mutated mCRPC who received at least one dose of protocol-specified treatment and had 6 months of follow-up prior to the data cutoff.","reportingStatus":"POSTED","timeFrame":"From enrollment to 6 months","title":"Clinical Benefit Rate (CBR) by IRR at 6 Months in Participants With a BRCA Alteration","type":"SECONDARY","unitOfMeasure":"percentage of participants"}